Smoking Cessation—Part III: Pharmacotherapy of Smoking Cessation

Workplace Health and Safety

Volumn 53, Issue 8, 2005, Pages 340-344

  Wilken, Lori ^a   Corbridge, Susan J ^a   Simpson, Sandra ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DRUG DERIVATIVE; NICOTINE;

HUMAN; REVIEW; SMOKING; SMOKING CESSATION;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; HUMANS; NICOTINE; SMOKING; SMOKING CESSATION;

EID: 25144463170     PISSN: 21650799     EISSN: 21650969     Source Type: Journal    
DOI: 10.1177/216507990505300805     Document Type: Article

References (16)

1. Benowitz N.L., & Dempsey D.A. (2004). Pharmacotherapy for smoking cessation during pregnancy. Nicotine & Tobacco Research, 6(1), S189–S202.
2. Berry J.K. (2005). Smoking cessation—Part II: Counseling in the workplace. AAOHN Journal, 53(5), 194–197.
3. Centers for Disease Control and Prevention. (2004). Cessation: Fact sheet. Retrieved June 8, 2005, from www.cdc.gov/tobacco/factsheets/cessation_factsheet.htm
4. da Costa C.L., Younes R.N., & Cruz-Lorenco M.T. (2002). Stopping smoking: A prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest, 122(2), 403–408.
5. Danielsson T., Rossner S., & Westin A. (1999). Open randomized trial of intermittent very low energy diet together with nicotine gum for stopping smoking in women who gained weight in previous attempts to quit. British Medical Journal, 319, 490–494.
6. Fiore M.C., Bailey W.C., & Cohen S.J. (2000). Treating tobacco use and dependence: Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services.
7. Henningfield J.E. (1995). Nicotine medications for smoking cessation. The New England Journal of Medicine, 333(18), 1196–1203.
8. Hilleman D.E., Mohiuddin S.M., Delcore M.G., & Lucas B.D. (1993). Randomized, controlled trial of transdermal Clonidine for smoking cessation. The Annals of Pharmacotherapy, 27, 1025–1028.
9. Jain A.K., Kaplan R.A., Gadde K.M., Wadden T.A., Allison D.B., Brewer E.R., Leadbetter R.A., Richard N., Haight B., Jamerson B.D., Busaron K.S., & Metz A. (2002). Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obese Research, 70(10), 1049–1056.
10. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., Smith S.S., Muramoto M.D., Daughton D.M., Doan K., Fiore M.C., & Baker T.B. (1999). A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. The New England Journal of Medicine, 340, 685–691.
11. Joseph A.M., Norman S.M., Ferry L.H., Prochazka A.V., Westman E.C., Steele B.G., Sherman S.E., Cleveland M., Antonnucio D.O., Hartman N., & McGovern P.G. (1996). The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. The New England Journal of Medicine, 335, 1792–1798.
12. Kimmel S.E., Berlin J.A., Miles C., Jaskowiak J., Carson J.L., & Strom B.L. (2001). Risk of acute first myocardial infarction and use of nicotine patches in a general population. Journal of the American Colleges of Cardiology, 37, 1297–1302.
13. Kimmon D. (2004). UC researchers report new drug helps smokers quit, limits weight gain. Retrieved May 26, 2005, from www.uc.edu/news/NR.asp?id=1417
14. Le Foll B., & Goldberg S.R. (2004). Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. Journal of Pharmacology and Experimental Therapeutics, 312(2), 875–883.
15. Oncken C., Watsky E., Reeves K., & Anziano R. for the Varenicline Study Group. (2005, May). Efficacy and safety of varenicline for smoking cessation. Poster presentation at the 2005 National Conference on Tobacco or Health, Chicago.
16. Sutherland G., Stapelton J.A., Russel M.A.H., Jarvis M.J., Hajek P., Belcher M., & Feyerabend C. (1992). Randomised controlled trial of nasal nicotine spray in smoking cessation. The Lancet, 340, 324–329.